Estimating the Detection Limit of Spectrofluorometers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Estimating the Detection Limit of Spectrofluorometers

A new Certified Reference Material from Starna Scientific allows the ultimate sensitivity of high-performance spectrofluorometers to be estimated. Traditionally, this was tested using very dilute solutions of fluorophores such as Quinine Sulfate. Near the detection limit, however, concentrations are so low that sample preparation becomes difficult, and there is a real risk of contamination.

When excited by UV or visible radiation, water emits a Raman peak that can be readily identified.  Because very few photons are involved in Raman scattering, the signal levels are very low, comparable to those produced by very low analyte concentrations in normal fluorescence measurements. The intensity and signal-to-noise ratio of the Raman signal therefore indicate the ultimate detection limit of the spectrofluorometer.

The reference material is a permanently sealed UV quartz 10mm fluorometer cuvette containing ultra-high purity water, supplied with a Certificate of Validation and full instructions for use. The certificate shows typical Raman spectra measured on a reference spectrophotometer traceable to NIST primary references, and signal-to-noise ratios calculated at two different excitation wavelengths.

Starna Scientific is accredited to ISO Guide 34 and ISO 17025.  Subject to appropriate storage and use, all Starna Certified Reference Materials carry a lifetime guarantee.

Starna Scientific Ltd.
www.starna.com
sales@starna.com
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
FindPharma Custom Search

Click here